SelectQuote, Inc.

SelectQuote, Inc. (SLQT) Market Cap

SelectQuote, Inc. has a market capitalization of $131.7M.

Price: $0.75

0.02 (2.81%)

Market Cap: 131.73M

NYSE · time unavailable

CEO: Timothy Robert Danker

Sector: Financial Services

Industry: Insurance - Brokers

IPO Date: 2020-05-21

Website: https://www.selectquote.com

SelectQuote, Inc. (SLQT) - Company Information

Market Cap: 131.73M|Sector: Financial Services

Company Profile

SelectQuote, Inc. operates as a tech-driven, direct-to-consumer marketplace, offering a wide spectrum of insurance products to individuals throughout the United States. These policies are underwritten by a variety of insurance carriers. The company structures its operations across three core divisions: Senior, Life, and Auto & Home. Within its Senior segment, SelectQuote provides access to a comprehensive suite of health policies, including Medicare Advantage, Medicare Supplement, and Medicare Part D plans. This segment also features ancillary coverages such as prescription drug plans, dental, vision, and hearing benefits. The Life division concentrates on term life insurance offerings, while the Auto & Home segment delivers personal automobile, homeowners', and general casualty insurance solutions. Established in 1999, SelectQuote, Inc. is headquartered in Overland Park, Kansas.

Analyst Sentiment

77%
Strong Buy

From 4 Active Polls

1Y Forecast: $3.00

▲ +301.6% Potential Upside

Consensus Target Metrics

Low Bound

$3

Median

$3

High Bound

$3

Average

$3

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$3.00
▲ +301.61% Upside
Low Target
$3.00
302% Risk
Median Target
$3.00
302% Mid
High Target
$3.00
302% Max
Consensus
Hold
4 / 11 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)132117262364438569634370516
Enterprise Value ($M)5004856987768229121,3621,0691,187
Price to Earnings Ratio (P/E)7.551.431.31-1.88-28.206.963.00-2.09-4.25
Price/Earnings-to-Growth Ratio (PEG)0.020.05
Price to Sales Ratio (P/S)0.080.270.491.111.271.391.321.271.68
Price to Book Ratio (P/B)0.210.180.420.670.761.021.941.371.63
Price to Free Cash Flow Ratio (P/FCF)-9.742.43138.62-14.22-11.548.11-20.47-19.2827.18
Enterprise Value to Sales (EV/Sales)1.131.302.362.382.232.833.663.86
Enterprise Value to EBITDA (EV/EBITDA)3.4711.847.10-36.0131.0415.2119.93-167.32237.29
Debt to Equity Ratio2.550.610.740.770.720.762.272.632.25

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

```html

📘 SELECTQUOTE INC (SLQT) — Investment Overview

🧩 Business Model Overview

SELECTQUOTE INC operates as an insurance distribution platform and broker, connecting consumers with insurance carriers through both digital and agent-assisted channels. The value chain is straightforward:

  • Lead generation via marketing (e.g., search, digital campaigns, and call center demand capture) targeted to specific insurance product needs.
  • Quoting and advice performed by licensed agents that translate consumer inputs into carrier-eligible submissions.
  • Carrier placement where SelectQuote earns compensation (typically commissions and related fees) when a policy is bound.
  • Operational scale that supports high-throughput underwriting workflows, compliance, and customer handling.

Customer “stickiness” is more constrained than in software, but the brokerage relationship can become durable in practice for segments where ongoing guidance and plan changes occur (notably Medicare-related shopping cycles) and where households re-engage around life and coverage events. The economic engine is primarily acquisition-to-bind conversion efficiency under regulatory and carrier contracting constraints.

💰 Revenue Streams & Monetisation Model

Revenue is commission-driven and product-mix dependent. Monetisation typically includes:

  • Insurance policy commissions earned at binding and, depending on product structure, ongoing consideration linked to the policy lifecycle.
  • Referral/placement economics where SelectQuote’s compensation is tied to successful placement versus mere quote activity.

Margin drivers center on the spread between:

  • Customer acquisition cost (CAC) and marketing efficiency (cost per lead, conversion rate, and attach rate to bound business),
  • Production cost (licensed agent labor, call center throughput, technology stack, and compliance overhead), and
  • Net commission economics determined by carrier agreements, product availability, and underwriting eligibility outcomes.

Because compensation is transaction-based, operating leverage tends to emerge when conversion improves, carrier terms hold, and production efficiency rises faster than acquisition costs.

🧠 Competitive Advantages & Market Positioning

SelectQuote’s moat is best characterized as an operational and distribution advantage rather than a classic “network effect” or “high switching cost” for consumers.

  • Scale in licensed distribution: Competition in insurance lead generation is won through execution—agent capacity, call center productivity, and compliance process maturity. Larger, well-run brokers can amortize fixed costs and increase throughput, improving unit economics.
  • Data/analytics to improve conversion: While consumers can shop freely, SelectQuote’s system can still create repeatable conversion advantage by using eligibility logic, product targeting, and workflow optimization to reduce wasted submissions.
  • Carrier contracting and product access: Consistent placement volume and operational reliability can strengthen relationships with insurers, supporting favorable commission terms and smoother quoting pathways.

Competitive benchmarking (primary competitors):

  • eHealth / GoHealth (digital-first Medicare-focused distribution): concentrates heavily on Medicare shopping workflows and online enrollment activity. SelectQuote’s positioning is broader across insurance categories, with agent-assisted distribution and a strong call center component.
  • Policygenius (digital insurance marketplace): focuses on consumer self-service and advice-led marketplace conversion. SelectQuote emphasizes distribution operations and licensed agent throughput to drive bind outcomes.
  • QuoteWizard (LendingTree) and similar quote aggregators: competes in property/casualty quote capture. SelectQuote’s industry focus includes segments where eligibility, guidance, and regulated enrollment processes raise the importance of operational execution.

Bottom line on moat difficulty: Consumer switching for insurance can be easy, but building a high-performance, compliant distribution engine with strong carrier outcomes is operationally non-trivial. The competitive barrier is less about brand and more about consistent execution across compliance, conversion, and carrier contracting.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is tied to both demographic trends and structural demand for distribution services:

  • Medicare population growth and continued benefit complexity: Aging demographics expand the addressable base that must evaluate Medicare options, creating a persistent need for guided comparison and enrollment support.
  • Insurance penetration and coverage reassessment events: Life insurance demand can rise with major life milestones and perceived under-insurance, supporting ongoing quote activity.
  • Outsourced distribution remains rational: Carriers benefit from brokers that can efficiently convert qualified consumers while managing appointment handling and eligibility workflows.
  • Operational technology and throughput improvements: Automation and better eligibility/triage can expand revenue without proportional labor increases, supporting margin durability when acquisition costs rise more slowly than conversion improvements.

TAM expansion comes not only from more insured households, but from the share of distribution that shifts toward intermediated, technology-assisted brokerage where consumers value guided enrollment and reduced friction.

⚠ Risk Factors to Monitor

  • Regulatory and compliance exposure: Insurance distribution is heavily regulated at the state level, including licensing, marketing rules, and consumer disclosure requirements. Changes in rules can alter allowable marketing tactics, lead handling, and enrollment processes.
  • Carrier concentration and contract economics: Commission rates, product availability, underwriting outcomes, and agreement terms can shift. If carrier terms tighten, unit economics can compress without offsetting conversion gains.
  • Marketing cost inflation and channel effectiveness risk: Lead generation relies on performance marketing, which can be pressured by competition, platform pricing changes, and shifts in search behavior. Conversion rate deterioration can amplify this impact.
  • Technology, data privacy, and cyber risk: The operating model depends on consumer data handling and secure systems for quoting workflows.
  • Operational execution during volume swings: Labor-intensive processes require stable production quality; throughput disruption can increase loss rates or reduce bind rates.

📊 Valuation & Market View

The market generally values insurance distribution brokers and lead generators using a mix of EV/Sales and EV/EBITDA, with emphasis on the sustainability of unit economics. Valuation sensitivity typically concentrates on:

  • Conversion metrics (lead-to-quote, quote-to-bind) and resulting revenue yield per customer acquisition dollar.
  • Marketing efficiency and the stability of CAC-to-commission economics.
  • Net commission rate trends driven by carrier contracting and product mix.
  • Operating leverage from improved throughput, automation, and call center productivity.

Because results are tied to transaction conversion, investors often underwrite forward performance using operating drivers rather than purely financial aggregates.

🔍 Investment Takeaway

SELECTQUOTE’s long-term investment case rests on the durability of a high-throughput, compliant insurance distribution engine that can translate demand capture into successful placements under carrier terms. The company’s competitive advantage is primarily operational scale and conversion-focused execution, reinforced by product access and contracting relationships. The key underwriting focus is whether conversion efficiency and net commission economics can remain stable enough to offset marketing cost pressure and regulatory complexity.


⚠ AI-generated — informational only. Validate using filings before investing.

```

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SLQT.

zacks.com2026-06-15

New Strong Buy Stocks for June 15th

EZPW, PLOW, NVT, ALTO and SLQT have been added to the Zacks Rank #1 (Strong Buy) List on June 15, 2026.

globenewswire.com2026-06-09

Kuehn Law Encourages Investors of SelectQuote, Inc. to Contact Law Firm

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SelectQuote, Inc. (NYSE: SLQT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at SelectQuote caused the company to misrepresent or fail to disclose that: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provided unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

zacks.com2026-05-29

SelectQuote (SLQT) Shows Fast-paced Momentum But Is Still a Bargain Stock

SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

zacks.com2026-05-15

SelectQuote (SLQT) Upgraded to Strong Buy: What Does It Mean for the Stock?

SelectQuote (SLQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

businesswire.com2026-05-14

SelectQuote Announces Participation in Upcoming RBC Global Healthcare Conference on May 20

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, announced today that Chief Financial Officer, Ryan Clement, and Head of Investor Relations, Matt Gunter, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, beginning at approximately 11:00am ET. Management will also be available for 1x1 and small.

zacks.com2026-05-13

Here Is Why Bargain Hunters Would Love Fast-paced Mover SelectQuote (SLQT)

SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

zacks.com2026-05-11

Should Value Investors Buy SelectQuote (SLQT) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

seekingalpha.com2026-05-05

SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript

SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript

zacks.com2026-05-05

SelectQuote (SLQT) Beats Q3 Earnings Estimates

SelectQuote (SLQT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.

businesswire.com2026-05-05

SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2026 of $430.9 million compared to consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million. Consolidated net income for the third quarter of fiscal year 2026 was $40.2 million compared to consolidated net income for the third quarter of fiscal year 2025 of $26.0 million. Finally, consolidated Adjusted EBITDA* for the third quarter of fi.

businesswire.com2026-04-21

SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing healthcare services platform, today announced it will release its fiscal third quarter 2026 financial results before market open on Tuesday, May 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (May 5, 2026) at 8:30 am ET to discuss the results. We en.

globenewswire.com2026-04-09

Kuehn Law Encourages Investors of SelectQuote, Inc. to Contact Law Firm

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  SelectQuote, Inc. (NYSE: SLQT) breached their fiduciary duties to shareholders.

businesswire.com2026-03-25

SelectQuote, Inc. Announces Receipt of Continued Listing Standard Notice from NYSE; Plans to Take Appropriate Actions to Cure

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the “Company”) announced today that the Company received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating that the Company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Company recently reported strong fiscal second quart.

prnewswire.com2026-03-18

Kuehn Law Encourages Investors of SelectQuote, Inc. to Contact Law Firm

NEW YORK, March 18, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  SelectQuote, Inc.  (NYSE: SLQT) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at SelectQuote caused the company to misrepresent or fail to disclose that: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provided unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

businesswire.com2026-03-17

SelectQuote Announces SelectQuote Local, Adding a New Strategic Growth Channel to Its Industry-Leading Insurance Platform

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced an initiative to expand its reach and complement its existing, telephonic insurance distribution model. SelectQuote Local will leverage the Company's industry-leading marketing, technology, customer service, and carrier relationships to offer consumers its senior health and life ins.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SLQT reported Q3’26 (ended 2026-03-31) revenue of $430.9M and net income of $21.4M. However, the income statement shows profitability deterioration versus both the prior quarter and the same quarter last year: net income fell from $69.3M in Q2’26 (QoQ -69.1%) and from $26.0M in Q3’25 (YoY -17.7%). Revenue also softened QoQ (from $537.1M in Q2’26, QoQ -19.8%) and was modestly higher YoY (from $408.2M in Q3’25, YoY +5.6%). Margin trends were mixed but ultimately contracting this quarter. Net margin declined to 4.97% (down from 12.90% in Q2’26 and down from 6.38% in Q3’25). Operating margin slipped to 8.34% (below Q2’26’s 14.02%) while gross margin improved to 80.7% (but note the prior-quarter gross margin data shows an extreme/possibly anomalous figure). Cash flow quality looks volatile: operating cash flow was $56.8M and free cash flow was $55.8M in Q3’26 (FCF supported by working-capital movements). Balance-sheet resilience is moderate: total assets were $1.33B with equity at $384.7M, while net debt was relatively low at ~$14.6M—down materially from Q2’26 (~$435.6M net debt), indicating strong balance-sheet de-risking. Total shareholder returns appear weak: the stock is down sharply over 1Y (-75.62%), and there is no dividend history provided (and buybacks appear minimal). With revenue/EPS profitability still inconsistent, shareholder performance and margin contraction keep the score below average."

Revenue Growth

Caution

Revenue fell QoQ to $430.9M (QoQ -19.8%) but rose YoY to $430.9M (YoY +5.6%), indicating mixed momentum.

Profitability

Neutral

Net income declined QoQ (-69.1%) and YoY (-17.7%). Net margin contracted to 4.97% from 12.90% (QoQ) and 6.38% (YoY), signaling weakening profitability despite some gross-margin improvement.

Cash Flow Quality

Fair

Q3’26 generated strong operating cash flow ($56.8M) and free cash flow ($55.8M). However, prior quarters show large swings (FCF near-zero or negative), so consistency remains a risk.

Leverage & Balance Sheet

Neutral

Total assets were $1.33B with equity of $384.7M. Net debt dropped to ~$14.6M from ~$435.6M in the prior quarter, improving balance-sheet resilience; current ratio ~1.59.

Shareholder Returns

Neutral

Market performance is sharply negative: 1Y change -75.62% and no dividend yield indicated. Buybacks are minimal (common stock repurchased ~$2.46M in the quarter), so total returns appear poor.

Analyst Sentiment & Valuation

Fair

Consensus price target is $4 versus a current price of $0.7778 (implying upside), but the stock’s severe drawdown and unstable fundamentals temper confidence.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

SelectQuote delivered a strong Q3 2026 despite mixed MA and policy season volatility. Consolidated revenue rose 6% to $431M and adjusted EBITDA climbed 18% YoY to $45M. Senior remained the profit anchor: $183M revenue (+8% YoY) and $59M adjusted EBITDA, with performance supported by a 1% policies-per-agent improvement and 14% lower marketing spend per approved policy versus two years ago. A positive $14M change in commissions receivable estimate boosted reported EBITDA; excluding it, Senior EBITDA margin was still 26% and management maintained 25%+ full-year EBITDA margins for four consecutive years. Healthcare Services showed resilience through IRA-driven top-line optics: revenue fell sequentially due to Jan 1 IRA max fair prices, but EBITDA impact was low single-digit millions and included $13M in manufacturer refunds. Guidance stayed unchanged: fiscal 2026 revenue $1.61B–$1.71B and adjusted EBITDA $90M–$100M, while SelectRx targets a $40M–$50M exit EBITDA run rate.

AI IconGrowth Catalysts

  • Senior: 1% improvement in policies per agent over the last two years despite seasonality volatility
  • Senior: marketing efficiency improved with spending 14% less per approved policy versus two years ago
  • Senior: higher Medicare Advantage OEP approval rates; management flagged possible timing/volume pull-forward into the quarter
  • SelectRx/Healthcare Services: Olathe, Kansas distribution facility efficiency gains (30%+ vs legacy locations) with less than 20% of prescriptions currently shipped from Olathe
  • SelectRx/Healthcare Services: sequential profitability resilience despite IRA-driven revenue optics, with adjusted EBITDA improving sequentially to $5 million
  • Operational: proprietary pharmacy management system in testing, expected to enable further Olathe scale after successful completion

Business Development

  • SelectRx: secured a multi-year agreement with its largest PBM partner (named partner not provided)
  • SelectRx: first patients have been routed through the new pharmacy management system workflow (successful pilot noted)
  • SelectQuote Local: franchise model launching via local community healthcare and life insurance participants (local providers) using SelectQuote technology/marketing/customer service on a fee-based arrangement

AI IconFinancial Highlights

  • Consolidated: revenue $431 million (+6% YoY); adjusted EBITDA $45 million (+18% YoY)
  • Consolidated margin note: consolidated EBITDA margin would have been 7% excluding a favorable adjustment to commissions receivable (i.e., underlying margin strong for an OEP quarter)
  • Senior: revenue $183 million (+8% YoY) with 4% growth in approved MA policies; supported by a positive $14 million change in estimate to commissions receivable
  • Senior: adjusted EBITDA $59 million; excluding the $14 million adjustment, EBITDA margin 26% and ~25%+ maintained for 4 consecutive years full-year basis
  • Senior valuation/accounting: commissions receivable nearly $1 billion at end of fiscal 3Q; LTV accounting assumes 10 renewal years and 15% constraint; management cited recapture rate >33%
  • Healthcare Services/SelectRx: Q-over-Q revenue decline driven optically by Inflation Reduction Act (IRA) price changes effective Jan 1; EBITDA impact in low single-digit millions and fully forecast
  • IRA/SelectRx: $13 million in drug-manufacturer refunds flowed through cost of goods line item
  • Healthcare Services: revenue $199 million (+5% YoY); adjusted EBITDA $5 million, sequential improvement despite headwinds
  • Life Insurance: revenue $48 million (+4% YoY); adjusted EBITDA $6 million; Final Expense commissions up >8% YoY with attractive margins, offset by Term Life pressure from shifting media consumption

AI IconCapital Funding

  • No buyback amounts or new debt/cash runway figures disclosed in the transcript
  • Management reiterated intent to delever over coming years and emphasized capital structure/cash interest obligation improvements contributing to 2027 cash flow acceleration

AI IconStrategy & Ops

  • Senior operational efficiency: 1% policies per agent improvement; marketing spend 14% less per approved policy versus two years ago
  • SelectRx distribution: Olathe, Kansas distribution facility came online April 2025; currently <20% of shipments, already 30%+ efficiency gains on those shipments; ample capacity given only 1 shift run
  • SelectRx scaling plan: pharmacy management system in testing phase to allow more SelectRx fulfillment through Olathe; management cited successful early patient routing
  • Guidance discipline: reaffirmed revenue range $1.61B–$1.71B and adjusted EBITDA range $90M–$100M despite Q3 benefited from higher-than-expected approval rates and a favorable receivables adjustment
  • Listing objective: management stated it will take all necessary action to maintain NYSE listing

AI IconMarket Outlook

  • Reaffirm fiscal 2026 guidance: revenue $1.61B–$1.71B and adjusted EBITDA $90M–$100M
  • SelectRx run-rate expectation: expects SelectRx to exit the year at a $40M–$50M EBITDA run rate (previously messaged)
  • 2027: management expects significant cash flow improvement/acceleration, encouraged by increasing visibility in the Medicare Advantage ecosystem

AI IconRisks & Headwinds

  • Medicare Advantage: elevated disruption backdrop over past two years; increased approval rates may partly reflect timing/volume pull-forward into Q3 (risk of softer Q4 approved policy levels)
  • SelectRx/Healthcare Services: IRA created sequential revenue optics via maximum fair prices for 10 higher-priced drugs (top-line decline) even though EBITDA impact is low single-digit millions
  • SelectRx: PBM reimbursement environment previously had a reimbursement rate change issue (management stated it has been resolved and rates normalized in Q3)
  • SelectRx: continued exposure to carrier-specific reimbursement actions
  • Life Insurance: Term Life remains competitive as consumers shift where/how they consume media; partially offset Final Expense tailwinds
  • Macro/industry: medical cost trends expected up high single digits YoY with reimbursement trend not fully sufficient to cover costs (mixed payer recovery)

Q&A: Analyst Interest

  • PBM reimbursement outlook: Management said the PBM reimbursement environment remains stable; the earlier reimbursement-rate issue has been resolved and Q3 showed normalization. They also emphasized securing a multi-year agreement with the largest PBM partner, without providing the partner’s name.
  • SelectRx IRA mechanics: Management clarified that the sequential revenue drop is mostly optical from IRA-driven price changes effective Jan 1, while EBITDA impact is low single-digit millions and was forecast. They disclosed $13 million in drug-manufacturer refunds flowing through cost of goods; geography changes add noise.
  • Senior LTV/receivables linkage and run-rate: Management explained the $14 million positive commissions receivable change was based on renewal-event visibility and updated persistency expectations, not a specific cohort. They chose not to modify $90M–$100M EBITDA guidance, and focused on Q4 approval-rate developments and renewal stability.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the SLQT Q3 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SLQT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (SLQT)

© 2026 Stock Market Info — SelectQuote, Inc. (SLQT) Financial Profile